Answers are grounded in this paper and cite their sources.
A double-blind, randomized, four-way crossover study was performed to assess the CNS effects of reboxetine, a unique selective noradrenaline reuptake inhibitor (NRI). Eighteen volunteers received reboxetine (1 or 3 mg), imipramine (75 mg) or placebo at weekly intervals. Pharmaco-electroencephalography was recorded under high- and low-vigilance conditions and spectral difference index, total power and alpha slow-wave index (ASI) were calculated. In addition, skilled performance on psychometric tests and well-being were assessed. Absolute and relative power were relatively unaffected by reboxetine but increased by imipramine. Total power and ASI were unaffected or slightly increased by reboxetine, but reduced by imipramine. Reboxetine and imipramine decreased fronto-central θ and fast β power. In pharmaco-electroencephalography, imipramine showed a left shift in the occipito-temporal lead, with an increase in δ and θ and a decrease in α power. Reboxetine increased α power. Following reboxetine administration, the results in performance tests either did not differ from placebo or were better (Pegboard test). After imipramine, a deterioration in the Steadiness and Pauli test occurred. Critical flicker fusion and Vienna test results were unaltered by either drug. In summary, reboxetine, unlike the tricyclic antidepressant imipramine, has no sedative effects of electroencephalography or on any behavioural variable indicative of a decline in vigilance. Furthermore, reboxetine showed a vigilance-enhancing effect.
No takes yet. Share an insight, caveat, or question.
Herrmann et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: